Slingshot members are tracking this event:
Celgene Releases Interim Analyses on Endpoints in Phase 3 ABOUND Study of ABRAXANE on Patients with Non-Small Cell Lung Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Feb 27, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Interim Analysis, Abound Study, Abraxane, Non-small Cell Lung Cancer